drugset
drugset / Trial / NCT07021794

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

NCT07021794 ↗

Phase 2 Recruiting 100 enrolled Nancy Klimas Florida Department of Health · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.

Timeline

Start
2025-06-16
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sipavibart Monoclonal antibody 300 mg Intramuscular

Indications

long COVID-19